BR112017004505A2 - agente terapêutico e método para prevenção e/ou tratamento de incontinência urinária, e, composto ou um sal do mesmo. - Google Patents

agente terapêutico e método para prevenção e/ou tratamento de incontinência urinária, e, composto ou um sal do mesmo.

Info

Publication number
BR112017004505A2
BR112017004505A2 BR112017004505-2A BR112017004505A BR112017004505A2 BR 112017004505 A2 BR112017004505 A2 BR 112017004505A2 BR 112017004505 A BR112017004505 A BR 112017004505A BR 112017004505 A2 BR112017004505 A2 BR 112017004505A2
Authority
BR
Brazil
Prior art keywords
urinary incontinence
salt
preventing
therapeutic agent
compound
Prior art date
Application number
BR112017004505-2A
Other languages
English (en)
Japanese (ja)
Inventor
Mori Shinobu
Kajihara Yusuke
Inamura Hiroko
Hirata Takuya
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of BR112017004505A2 publication Critical patent/BR112017004505A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção aborda o problema de prover uma composição farmacêutica nova para prevenção e/ou tratamento de incontinência urinária, a dita composição farmacêutica sendo diferente de fármacos convencionais. a presente invenção provê um agente preventivo e/ou agente terapêutico para incontinência urinária que tem, como um ingrediente ativo, 1-[2-({[trans-3-fluoro-1-(3-fluoropiridin-2-il)ciclobutil]metil}amino)pirimidin-5-il]-1h-pirrol-3-carboxamida ou um sal do mesmo.
BR112017004505-2A 2014-09-09 2015-09-09 agente terapêutico e método para prevenção e/ou tratamento de incontinência urinária, e, composto ou um sal do mesmo. BR112017004505A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014-183434 2014-09-09
JP2014183434 2014-09-09
PCT/JP2015/075567 WO2016039367A1 (ja) 2014-09-09 2015-09-09 尿失禁予防用及び／又は治療用新規医薬組成物

Publications (1)

Publication Number Publication Date
BR112017004505A2 true BR112017004505A2 (pt) 2018-01-23

Family

ID=55459111

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004505-2A BR112017004505A2 (pt) 2014-09-09 2015-09-09 agente terapêutico e método para prevenção e/ou tratamento de incontinência urinária, e, composto ou um sal do mesmo.

Country Status (18)

Country Link
US (1) US9987279B2 (pt)
EP (1) EP3192512B1 (pt)
JP (1) JP6573618B2 (pt)
KR (1) KR102460731B1 (pt)
CN (1) CN106687115B (pt)
AU (1) AU2015313221B2 (pt)
BR (1) BR112017004505A2 (pt)
CA (1) CA2957804C (pt)
ES (1) ES2750751T3 (pt)
IL (1) IL250919B (pt)
MX (1) MX2017002853A (pt)
PH (1) PH12017500436A1 (pt)
PL (1) PL3192512T3 (pt)
PT (1) PT3192512T (pt)
RU (1) RU2738886C9 (pt)
SG (1) SG11201701019UA (pt)
WO (1) WO2016039367A1 (pt)
ZA (1) ZA201701671B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
TWI773118B (zh) 2016-02-12 2022-08-01 美商細胞動力學股份有限公司 四氫異喹啉衍生物
EP3732166A4 (en) * 2017-12-26 2021-09-01 Cytokinetics, Incorporated PROCESS FOR THE MANUFACTURING OF AN AMINO-PYRIMIDINE AND INTERMEDIATES THEREOF
CN116635378A (zh) 2020-11-06 2023-08-22 赛特凯恩蒂克公司 二环1,4-二氮杂环庚酮和其治疗用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005095359A1 (en) 2004-03-05 2005-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
US20080009538A1 (en) * 2005-03-21 2008-01-10 Phil Skolnick Methods and compositions for the treatment of urinary incontinence
JP2007176933A (ja) * 2005-11-29 2007-07-12 Tanabe Seiyaku Co Ltd 医薬組成物
JP2007290970A (ja) * 2006-04-21 2007-11-08 Astellas Pharma Inc 腹圧性及び混合型尿失禁治療剤
CA2672591A1 (en) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Treating agent of uropathy
US20100240697A1 (en) 2007-11-02 2010-09-23 Astellas Pharma Inc. Pharmaceutical composition for treating overactive bladder
JP5553547B2 (ja) 2009-07-14 2014-07-16 俊一 梶岡 トロポニン含有医薬組成物
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
CN108553467A (zh) 2012-04-02 2018-09-21 赛特凯恩蒂克公司 改善膈肌功能的方法
KR102163931B1 (ko) 2012-04-11 2020-10-12 싸이토키네틱스, 인코포레이티드 골격근 피로에 대한 저항을 개선

Also Published As

Publication number Publication date
ES2750751T3 (es) 2020-03-27
IL250919A0 (en) 2017-04-30
RU2738886C2 (ru) 2020-12-18
WO2016039367A1 (ja) 2016-03-17
US9987279B2 (en) 2018-06-05
RU2017111848A3 (pt) 2019-07-17
KR102460731B1 (ko) 2022-10-28
EP3192512A4 (en) 2018-02-07
EP3192512B1 (en) 2019-08-14
RU2738886C9 (ru) 2021-12-06
JPWO2016039367A1 (ja) 2017-06-15
PH12017500436A1 (en) 2017-07-31
ZA201701671B (en) 2019-06-26
IL250919B (en) 2019-10-31
PL3192512T3 (pl) 2020-03-31
CA2957804A1 (en) 2016-03-17
PT3192512T (pt) 2019-10-29
SG11201701019UA (en) 2017-03-30
AU2015313221A1 (en) 2017-03-09
MX2017002853A (es) 2018-01-12
CN106687115B (zh) 2019-07-19
RU2017111848A (ru) 2018-10-08
EP3192512A1 (en) 2017-07-19
JP6573618B2 (ja) 2019-09-11
CA2957804C (en) 2023-04-04
AU2015313221B2 (en) 2019-11-21
CN106687115A (zh) 2017-05-17
US20170273979A1 (en) 2017-09-28
KR20170045353A (ko) 2017-04-26

Similar Documents

Publication Publication Date Title
BR112017004505A2 (pt) agente terapêutico e método para prevenção e/ou tratamento de incontinência urinária, e, composto ou um sal do mesmo.
CO2019008487A2 (es) Compuesto de quinazolina
PH12017501306A1 (en) Inhibitors of histone demethylases
BR112016029334A2 (pt) produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos
BR112017017078A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, gerenciar, tratar ou amenizar uma doença.
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2017008057A (es) Derivados de azabiciclooctano como agonistas de fxr para el uso en el tratamiento de enfermedades hepaticas y gastrointestinales.
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
ES2969701T3 (es) Derivado de N2,N4-difenilpirimidin-2,4-diamina, método de preparación del mismo y composición farmacéutica que lo contiene como principio activo para la prevención o el tratamiento del cáncer
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
PH12019501102A1 (en) Magl inhibitors
TN2019000153A1 (en) Magl inhibitors
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CR20150505A (es) Derivado de dihidropiridazin-3,5-diona
MX2016001446A (es) Inhibidores de heterobicicloaril rorc2 y metodos de uso de los mismos.
BR112017028468A2 (pt) formulação sólida oral, e método para preparar uma formulação sólida oral
BR112019024566A2 (pt) inibidores de pirazol magl
PH12019500326A1 (en) Combination of fxr agonists
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
BR112017007916A2 (pt) compostos sarms para tratamento de distúrbios urológicos
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]